SOPHiA GENETICS Enhances RareCyte Precision Biology Services Portfolio
RareCyte will use the SOPHiA DDM™ Platform to support its oncology testing panel
BOSTON and ROLLE, Switzerland, Jan. 18, 2024 /PRNewswire/ — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that RareCyte Inc., a precision biology company based in Seattle, Washington, is live on SOPHiA GENETICS. RareCyte has implemented the SOPHiA DDM™ Platform to complement its Precision Biology Services portfolio.
Related news for (SOPH)
- Molecules, Machines & Markets: Biotech Booms, AI Accelerates, and Pain Relief Gets Personal
- SOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in Spain
- SOPHiA GENETICS Supports Genetic Testing in Brazil
- SOPHiA GENETICS to Present at the J.P. Morgan 2024 Healthcare Conference
